When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ABBV - FDA lifts partial hold on AbbVie's study of venetoclax in multiple myeloma
AbbVie Inc.
The FDA has removed the partial clinical hold on AbbVie's (NYSE:ABBV) Phase 3 clinical trial, CANOVA, evaluating the combination of Venclexta/Venclyxto (venetoclax) and dexamethasone versus Celgene's (NASDAQ:CELG) Pomalyst (pomalidomide) + dexamethasone in patients with relapsed/refractory multiple myeloma (MM) who are positive for the translocation [t(11;14)] abnormality, a type of MM associated with a poor prognosis.
More news on: AbbVie Inc., Celgene Corporation, Healthcare stocks news,